March 29, 2024
Sumitomo Pharma said on March 28 that it is now set to launch a company-sponsored PI/II clinical study in the US for allogeneic iPS cell-derived dopaminergic progenitor cells DSP-1083 for the treatment of Parkinson’s disease. The US FDA has cleared...read more